Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy”

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks that Jim Cramer discusses.

During the lightning round, a caller asked about Biohaven Ltd. (NYSE:BHVN), and Cramer commented:

“Alright, Biohaven had an analyst day the other day, and it was, you know, people didn’t get excited about it. Now, in full disclosure, I do have a personal deal with Biohaven, and I don’t talk about it much because it’s not been disclosed, but I am surprised this stock is all the way down here. Vlad Coric is really good. I think that this is a buy, but you could say, hey Cramer, you’re biased, you got a deal with them. But I’m just telling you that’s how I feel, or else I wouldn’t have a deal with them.”

A pharmacist in a white coat with a range of drugs on shelves behind her.

Biohaven (NYSE:BHVN) works on creating and advancing treatments in the fields of immunology, neuroscience, and cancer. On April 22, Cramer was asked about the company, and he said:

“Alright, first, in pure disclosure, Biohaven, I’m working with them. They’ve bought a drug from me, that I made for me, and a terrific guy, Larry Newman, Dr. Newman, to help solve tinnitus so I always want to tell people that. The stock at $21, I think, therefore, is too cheap. But you might say, oh, that’s just Jim talking because he sold his drug to them. But no, I think the stock is very cheap, and Vlad Coric, who’s the CEO, I think, is really terrific. So I would be a buyer of the stock.”

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.